Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by priceless2on Feb 20, 2015 10:54am
160 Views
Post# 23447996

RE:RE:INTERESTING ARTICLE RE cholesterol EFFLUX AS MEASURE OF HDL

RE:RE:INTERESTING ARTICLE RE cholesterol EFFLUX AS MEASURE OF HDL It would be nice if RVX would put this information on their blog so the rest of there shareholders might no some more information. It amazes me why management  are so secretive and scare about relaying shareholder info yet they don't understand why the shareprice is where it is at

What  would be the market cap of  any normal smal biotech  for a diabetes drug develpment co going into a phase 3 trial with no safety issues to date, and having the MACE # they have from the past 2 trials.  75 million, ?? 250 million  500 million ??? why is shareholder value so low for a  small molecule compound with such huge potential.(assuming a positive phase  3 trial)  Something is not adding up!!
Bullboard Posts